A citation-based method for searching scientific literature

Nelson B Watts, John P Bilezikian, Keith Usiskin, Robert Edwards, Mehul Desai, Gordon Law, Gary Meininger. J Clin Endocrinol Metab 2016
Times Cited: 241







List of co-cited articles
1240 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
57

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
51

Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.
John P Bilezikian, Nelson B Watts, Keith Usiskin, David Polidori, Albert Fung, Daniel Sullivan, Norm Rosenthal. J Clin Endocrinol Metab 2016
154
43

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
39



Possible adverse effects of SGLT2 inhibitors on bone.
Simeon I Taylor, Jenny E Blau, Kristina I Rother. Lancet Diabetes Endocrinol 2015
167
31

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
29

Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis.
Darin Ruanpeng, Patompong Ungprasert, Jutarat Sangtian, Tasma Harindhanavudhi. Diabetes Metab Res Rev 2017
72
37

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
22

Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture.
Mohsen Janghorbani, Rob M Van Dam, Walter C Willett, Frank B Hu. Am J Epidemiol 2007
769
21

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
20

Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.
Ö Ljunggren, J Bolinder, L Johansson, J Wilding, A M Langkilde, C D Sjöström, J Sugg, S Parikh. Diabetes Obes Metab 2012
139
19

Mechanisms of diabetes mellitus-induced bone fragility.
Nicola Napoli, Manju Chandran, Dominique D Pierroz, Bo Abrahamsen, Ann V Schwartz, Serge L Ferrari. Nat Rev Endocrinol 2017
391
19

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
19



Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study.
Jenny E Blau, Viviana Bauman, Ellen M Conway, Paolo Piaggi, Mary F Walter, Elizabeth C Wright, Shanna Bernstein, Amber B Courville, Michael T Collins, Kristina I Rother,[...]. JCI Insight 2018
59
28

Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes.
Ann V Schwartz, Eric Vittinghoff, Douglas C Bauer, Teresa A Hillier, Elsa S Strotmeyer, Kristine E Ensrud, Meghan G Donaldson, Jane A Cauley, Tamara B Harris, Annemarie Koster,[...]. JAMA 2011
401
17


Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
J Bolinder, Ö Ljunggren, L Johansson, J Wilding, A M Langkilde, C D Sjöström, J Sugg, S Parikh. Diabetes Obes Metab 2014
307
16

Fracture risk in diabetic elderly men: the MrOS study.
Nicola Napoli, Elsa S Strotmeyer, Kristine E Ensrud, Deborah E Sellmeyer, Douglas C Bauer, Andrew R Hoffman, Thuy-Tien L Dam, Elizabeth Barrett-Connor, Lisa Palermo, Eric S Orwoll,[...]. Diabetologia 2014
149
15

Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials.
Bin Su, Hui Sheng, Manna Zhang, Le Bu, Peng Yang, Liang Li, Fei Li, Chunjun Sheng, Yuqi Han, Shen Qu,[...]. Endocrine 2015
107
14

High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus.
Andrew J Burghardt, Ahi S Issever, Ann V Schwartz, Kevin A Davis, Umesh Masharani, Sharmila Majumdar, Thomas M Link. J Clin Endocrinol Metab 2010
295
14

Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study.
Michael Fralick, Seoyoung C Kim, Sebastian Schneeweiss, Dae Kim, Donald A Redelmeier, Elisabetta Patorno. Ann Intern Med 2019
52
26

Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials.
Matteo Monami, Ilaria Dicembrini, Alessandro Antenore, Edoardo Mannucci. Diabetes Care 2011
182
13


In vivo assessment of bone quality in postmenopausal women with type 2 diabetes.
Joshua N Farr, Matthew T Drake, Shreyasee Amin, L Joseph Melton, Louise K McCready, Sundeep Khosla. J Bone Miner Res 2014
312
12

The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes.
Kathryn M Thrailkill, Jeffry S Nyman, R Clay Bunn, Sasidhar Uppuganti, Katherine L Thompson, Charles K Lumpkin, Evangelia Kalaitzoglou, John L Fowlkes. Bone 2017
36
33

SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice.
Kathryn M Thrailkill, R Clay Bunn, Jeffry S Nyman, Mallikarjuna R Rettiganti, Gael E Cockrell, Elizabeth C Wahl, Sasidhar Uppuganti, Charles K Lumpkin, John L Fowlkes. Bone 2016
43
27

Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study.
Matteo Monami, Barbara Cresci, Angela Colombini, Laura Pala, Daniela Balzi, Francesca Gori, Veronica Chiasserini, Niccolò Marchionni, Carlo Maria Rotella, Edoardo Mannucci. Diabetes Care 2008
137
12

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.
Peter Ueda, Henrik Svanström, Mads Melbye, Björn Eliasson, Ann-Marie Svensson, Stefan Franzén, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Björn Pasternak. BMJ 2018
167
12

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
12



Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
11

Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study.
Elsa S Strotmeyer, Jane A Cauley, Ann V Schwartz, Michael C Nevitt, Helaine E Resnick, Douglas C Bauer, Frances A Tylavsky, Nathalie de Rekeneire, Tamara B Harris, Anne B Newman. Arch Intern Med 2005
272
11

Prospective study of diabetes and risk of hip fracture: the Nurses' Health Study.
Mohsen Janghorbani, Diane Feskanich, Walter C Willett, Frank Hu. Diabetes Care 2006
228
11

Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.
Robert G Josse, Sumit R Majumdar, Yinggan Zheng, Amanda Adler, M Angelyn Bethel, John B Buse, Jennifer B Green, Keith D Kaufman, Helena W Rodbard, Tsvetalina Tankova,[...]. Diabetes Obes Metab 2017
39
25

Initiation of dapagliflozin and treatment-emergent fractures.
Konstantinos A Toulis, John P Bilezikian, G Neil Thomas, Wasim Hanif, Kalliopi Kotsa, Rasiah Thayakaran, Deepiksana Keerthy, Abd A Tahrani, Krishnarajah Nirantharakumar. Diabetes Obes Metab 2018
23
43

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
Steven E Kahn, Bernard Zinman, John M Lachin, Steven M Haffner, William H Herman, Rury R Holman, Barbara G Kravitz, Dahong Yu, Mark A Heise, R Paul Aftring,[...]. Diabetes Care 2008
381
10

Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study.
Ann V Schwartz, Haiying Chen, Walter T Ambrosius, Ajay Sood, Robert G Josse, Denise E Bonds, Adrian M Schnall, Eric Vittinghoff, Douglas C Bauer, Mary Ann Banerji,[...]. J Clin Endocrinol Metab 2015
52
19

Fracture risk in type 2 diabetes: update of a population-based study.
L Joseph Melton, Cynthia L Leibson, Sara J Achenbach, Terry M Therneau, Sundeep Khosla. J Bone Miner Res 2008
248
10

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
372
10

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, John P Wilding, Kamlesh Khunti, Reinhard W Holl, Anna Norhammar, Kåre I Birkeland, Marit Eika Jørgensen, Marcus Thuresson,[...]. Circulation 2017
502
10

Diagnosis and management of bone fragility in diabetes: an emerging challenge.
S L Ferrari, B Abrahamsen, N Napoli, K Akesson, M Chandran, R Eastell, G El-Hajj Fuleihan, R Josse, D L Kendler, M Kraenzlin,[...]. Osteoporos Int 2018
130
10

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur Heart J 2020
10

Older women with diabetes have an increased risk of fracture: a prospective study.
A V Schwartz, D E Sellmeyer, K E Ensrud, J A Cauley, H K Tabor, P J Schreiner, S A Jamal, D M Black, S R Cummings. J Clin Endocrinol Metab 2001
529
10

Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial.
Ofri Mosenzon, Cheryl Wei, Jaime Davidson, Benjamin M Scirica, Ilan Yanuv, Aliza Rozenberg, Boaz Hirshberg, Avivit Cahn, Christina Stahre, Krzysztof Strojek,[...]. Diabetes Care 2015
44
20

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
Jason H Y Wu, Celine Foote, Juuso Blomster, Tadashi Toyama, Vlado Perkovic, Johan Sundström, Bruce Neal. Lancet Diabetes Endocrinol 2016
296
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.